Publicaciones en colaboración con investigadores/as de Icahn School of Medicine at Mount Sinai (84)

2024

  1. A naturalistic cohort study of first-episode schizophrenia spectrum disorder: A description of the early phase of illness in the PSYSCAN cohort

    Schizophrenia Research, Vol. 266, pp. 237-248

  2. Accelerated Cortical Thinning in Schizophrenia Is Associated With Rare and Common Predisposing Variation to Schizophrenia and Neurodevelopmental Disorders

    Biological Psychiatry, Vol. 96, Núm. 5, pp. 376-389

  3. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

    Schizophrenia bulletin, Vol. 50, Núm. 3, pp. 496-512

  4. Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS

    Early Intervention in Psychiatry, Vol. 18, Núm. 4, pp. 255-272

  5. Large-scale analysis of structural brain asymmetries during neurodevelopment: Associations with age and sex in 4265 children and adolescents

    Human Brain Mapping, Vol. 45, Núm. 11

  6. Mapping gray and white matter volume abnormalities in early-onset psychosis: an ENIGMA multicenter voxel-based morphometry study

    Molecular Psychiatry, Vol. 29, Núm. 2, pp. 496-504

  7. Multivariable prediction of functional outcome after first-episode psychosis: a crossover validation approach in EUFEST and PSYSCAN

    Schizophrenia, Vol. 10, Núm. 1

  8. PsyCog: A computerised mini battery for assessing cognition in psychosis

    Schizophrenia Research: Cognition, Vol. 37

  9. Relapse in clinically stable adult patients with schizophrenia or schizoaffective disorder: evidence-based criteria derived by equipercentile linking and diagnostic test accuracy meta-analysis

    The Lancet Psychiatry, Vol. 11, Núm. 1, pp. 36-46

  10. Verbal Learning and Memory Deficits across Neurological and Neuropsychiatric Disorders: Insights from an ENIGMA Mega Analysis

    Brain Sciences, Vol. 14, Núm. 7

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Cannabis use as a potential mediator between childhood adversity and first-episode psychosis: Results from the EU-GEI case-control study

    Psychological Medicine, Vol. 53, Núm. 15, pp. 7375-7384

  3. Child maltreatment, migration and risk of first-episode psychosis: results from the multinational EU-GEI study

    Psychological Medicine, Vol. 53, Núm. 13, pp. 6150-6160

  4. Development and Validation of Predictive Model for a Diagnosis of First Episode Psychosis Using the Multinational EU-GEI Case-control Study and Modern Statistical Learning Methods

    Schizophrenia Bulletin Open, Vol. 4, Núm. 1

  5. Differences in Patterns of Stimulant Use and Their Impact on First-Episode Psychosis Incidence: An Analysis of the EUGEI Study

    Schizophrenia Bulletin, Vol. 49, Núm. 5, pp. 1269-1280

  6. Extreme deviations from the normative model reveal cortical heterogeneity and associations with negative symptom severity in first-episode psychosis from the OPTiMiSE and GAP studies

    Translational Psychiatry, Vol. 13, Núm. 1

  7. First-Episode Psychosis Patients Who Deteriorated in the Premorbid Period Do Not Have Higher Polygenic Risk Scores Than Others: A Cluster Analysis of EU-GEI Data

    Schizophrenia bulletin, Vol. 49, Núm. 1, pp. 218-227

  8. Large-scale analysis of structural brain asymmetries in schizophrenia via the ENIGMA consortium

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 120, Núm. 14

  9. Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex: The OPTiMiSE study

    Psychological Medicine, Vol. 53, Núm. 8, pp. 3471-3479

  10. Schizophrenia risk conferred by rare protein-truncating variants is conserved across diverse human populations

    Nature genetics, Vol. 55, Núm. 3, pp. 369-376